Pasithea Therapeutics Corp SEC Filings

KTTAW NASDAQ

Welcome to our dedicated page for Pasithea Therapeutics SEC filings (Ticker: KTTAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing a biotech 10-K packed with pharmacology jargon can feel like another clinical trial. Pasithea Therapeutics’ filings are especially intricate, detailing PAS-004 development costs, cash runway scenarios, and licensing clauses that change with every milestone. If you have ever searched, “How do I find Pasithea Therapeutics’ quarterly earnings report 10-Q filing?” or “Why did an executive exercise KTTAW warrants on a Form 4?”, you know the challenge.

Stock Titan’s AI solves this problem in seconds. Our platform streams every Pasithea Therapeutics SEC filing—10-K annual reports, 10-Q quarterlies, 8-K material event disclosures, and real-time Form 4 insider transactions—directly from EDGAR, then distills what matters. Need the R&D spend trend or details on that neurofibromatosis type 1 trial update? The AI summary points you there, while clickable highlights explain each accounting footnote in plain language. Investors asking, “What does Pasithea Therapeutics report about PAS-004 toxicology?” or “Where is Pasithea Therapeutics executive compensation proxy statement?” get immediate, searchable answers.

You’ll also find:

Pasithea Therapeutics insider trading Form 4 transactions with warrant exercise timestamps
Pasithea Therapeutics quarterly earnings report 10-Q filing cash-burn analysis
Pasithea Therapeutics 8-K material events explained, from trial suspensions to licensing deals
Pasithea Therapeutics annual report 10-K simplified, including going-concern and dilution risk notes
Understanding Pasithea Therapeutics SEC documents with AI—no medical dictionary required

Whether you’re monitoring Pasithea Therapeutics executive stock transactions Form 4, comparing pipeline costs across quarters, or studying the proxy statement executive compensation tables, Stock Titan delivers the depth professionals need without the time sink.

06/27/2025 04:05 PM

Filing

[8-K] Pasithea Therapeutics Corp. Warrants Reports Material Event

Rhea-AI Summary

Pasithea Therapeutics (Nasdaq:KTTA) filed an 8-K reporting receipt of a Nasdaq bid-price deficiency notice on 23-Jun-2025. The company’s shares traded below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5550(a)(2). Pasithea has 180 days—until 22-Dec-2025—to regain compliance by posting a closing bid of at least $1.00 for 10 straight sessions. A second 180-day extension is possible if other listing standards are met and the firm commits to a remedy such as a reverse split. There is no immediate delisting; business operations and SEC reporting remain unaffected. Management is monitoring share price and evaluating options to restore compliance.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

[8-K] Pasithea Therapeutics Corp. Warrants Reports Material Event

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

[424B5] Pasithea Therapeutics Corp. Warrants Prospectus Supplement (Debt Securities)

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Pasithea Therapeutics (KTTAW)?

The current stock price of Pasithea Therapeutics (KTTAW) is $0.0216 as of June 25, 2025.

What is the core focus of Pasithea Therapeutics Corp?

Pasithea Therapeutics focuses on the discovery, research, and development of novel treatments for CNS disorders and RASopathies, leveraging advanced drug development and translational medicine.

Which therapeutic areas are prioritized by the company?

The company prioritizes areas such as neurofibromatosis type 1, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), schizophrenia, and cancer indications associated with its novel MEK inhibitor.

How does Pasithea generate its business value?

As a clinical-stage biotechnology firm, its value is derived from strategic research partnerships, milestone achievements in clinical trials, and licensing opportunities as its pipeline compounds progress through development.

What is the significance of PAS-004 in the company’s pipeline?

PAS-004 is a next-generation macrocyclic MEK inhibitor developed by Pasithea Therapeutics, representing a key component in their strategy to target neurofibromatosis type 1 and extend its application to various cancer indications.

How does the company approach clinical trials?

Pasithea Therapeutics operates a decentralized clinical trial model with sites in multiple regions, ensuring diverse patient recruitment and robust data collection, which is central to validating its therapeutic candidates.

What differentiates Pasithea Therapeutics within the biotech industry?

Its distinction lies in combining deep scientific expertise with a focused approach on complex CNS and oncological diseases, positioning it uniquely among clinical-stage companies with innovative drug development strategies.

Who are Pasithea Therapeutics' key competitors?

The competitive landscape includes other clinical-stage biotechnology companies developing treatments for CNS disorders and cancer, though Pasithea differentiates itself through its specialized translational research and diversified pipeline.